Revelation Biosciences Stock Performance
| REVB Stock | USD 0.52 0.03 5.45% |
The company holds a Beta of 2.27, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Revelation Biosciences will likely underperform. At this point, Revelation Biosciences has a negative expected return of -1.26%. Please make sure to check Revelation Biosciences' potential upside, daily balance of power, as well as the relationship between the Daily Balance Of Power and price action indicator , to decide if Revelation Biosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Revelation Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in February 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Last Split Factor 1:3 | Last Split Date 2025-07-07 |
1 | Can Revelation Biosciences Inc. stock continue upward trend - Gap Up Smart Investment Allocation Insights - newser.com | 11/03/2025 |
2 | How Revelation Biosciences Inc. Equity Warrant stock performs in weak economy - Dividend Hike Safe Capital Growth Tips - newser.com | 11/18/2025 |
3 | Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting | 12/01/2025 |
4 | Revelation Biosciences sets warrant expiration after stockholder approval - Investing.com | 12/11/2025 |
5 | HOKA Recommended Models Is Revelation Biosciences Inc. Equity Warrant stock a buy for dividend growth - Daily Trainer Picks trail grip notes for mixed terrain -... | 01/09/2026 |
6 | Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635 | 01/12/2026 |
7 | Revelation Bio To Share New Data From PRIME Study Of Gemini In March - Nasdaq | 01/15/2026 |
8 | Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI | 01/21/2026 |
9 | Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026 | 01/26/2026 |
| Begin Period Cash Flow | 12 M | |
| Total Cashflows From Investing Activities | -19.2 K |
Revelation | Build AI portfolio with Revelation Stock |
Revelation Biosciences Relative Risk vs. Return Landscape
If you would invest 128.00 in Revelation Biosciences on October 29, 2025 and sell it today you would lose (74.00) from holding Revelation Biosciences or give up 57.81% of portfolio value over 90 days. Revelation Biosciences is currently does not generate positive expected returns and assumes 5.2762% risk (volatility on return distribution) over the 90 days horizon. In different words, 47% of stocks are less volatile than Revelation, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Revelation Biosciences Target Price Odds to finish over Current Price
The tendency of Revelation Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.52 | 90 days | 0.52 | close to 99 |
Based on a normal probability distribution, the odds of Revelation Biosciences to move above the current price in 90 days from now is close to 99 (This Revelation Biosciences probability density function shows the probability of Revelation Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 2.27 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Revelation Biosciences will likely underperform. Additionally Revelation Biosciences has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Revelation Biosciences Price Density |
| Price |
Predictive Modules for Revelation Biosciences
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Revelation Biosciences. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Revelation Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Revelation Biosciences Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Revelation Biosciences is not an exception. The market had few large corrections towards the Revelation Biosciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Revelation Biosciences, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Revelation Biosciences within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -1.26 | |
β | Beta against Dow Jones | 2.27 | |
σ | Overall volatility | 0.15 | |
Ir | Information ratio | -0.22 |
Revelation Biosciences Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Revelation Biosciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Revelation Biosciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Revelation Biosciences generated a negative expected return over the last 90 days | |
| Revelation Biosciences has high historical volatility and very poor performance | |
| Revelation Biosciences has some characteristics of a very speculative penny stock | |
| Revelation Biosciences has a very high chance of going through financial distress in the upcoming years | |
| Revelation Biosciences currently holds 1.91 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Revelation Biosciences has a current ratio of 0.67, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Revelation Biosciences' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (15.04 M) with profit before overhead, payroll, taxes, and interest of 90.91 M. | |
| Revelation Biosciences currently holds about 3.48 M in cash with (18.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.15. | |
| Revelation Biosciences has a frail financial position based on the latest SEC disclosures | |
| Roughly 25.0% of Revelation Biosciences outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026 |
Revelation Biosciences Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Revelation Stock often depends not only on the future outlook of the current and potential Revelation Biosciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Revelation Biosciences' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 171.5 K | |
| Cash And Short Term Investments | 6.5 M |
Revelation Biosciences Fundamentals Growth
Revelation Stock prices reflect investors' perceptions of the future prospects and financial health of Revelation Biosciences, and Revelation Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Revelation Stock performance.
| Return On Equity | -1.19 | ||||
| Return On Asset | -0.53 | ||||
| Current Valuation | (8.88 M) | ||||
| Shares Outstanding | 5.92 M | ||||
| Price To Earning | 8.69 X | ||||
| Price To Book | 0.35 X | ||||
| Price To Sales | 2.88 X | ||||
| Gross Profit | 90.91 M | ||||
| EBITDA | (7.95 M) | ||||
| Net Income | (15.04 M) | ||||
| Cash And Equivalents | 3.48 M | ||||
| Cash Per Share | 0.15 X | ||||
| Total Debt | 1.91 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 0.68 X | ||||
| Book Value Per Share | 3.07 X | ||||
| Cash Flow From Operations | (18.32 M) | ||||
| Earnings Per Share | 81.25 X | ||||
| Market Capitalization | 3.83 M | ||||
| Total Asset | 6.62 M | ||||
| Retained Earnings | (40.51 M) | ||||
| Working Capital | 4.65 M | ||||
About Revelation Biosciences Performance
By analyzing Revelation Biosciences' fundamental ratios, stakeholders can gain valuable insights into Revelation Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Revelation Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Revelation Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.61) | (2.74) | |
| Return On Capital Employed | (1.95) | (1.85) | |
| Return On Assets | (2.61) | (2.74) | |
| Return On Equity | (3.67) | (3.49) |
Things to note about Revelation Biosciences performance evaluation
Checking the ongoing alerts about Revelation Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Revelation Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Revelation Biosciences generated a negative expected return over the last 90 days | |
| Revelation Biosciences has high historical volatility and very poor performance | |
| Revelation Biosciences has some characteristics of a very speculative penny stock | |
| Revelation Biosciences has a very high chance of going through financial distress in the upcoming years | |
| Revelation Biosciences currently holds 1.91 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Revelation Biosciences has a current ratio of 0.67, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Revelation Biosciences' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (15.04 M) with profit before overhead, payroll, taxes, and interest of 90.91 M. | |
| Revelation Biosciences currently holds about 3.48 M in cash with (18.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.15. | |
| Revelation Biosciences has a frail financial position based on the latest SEC disclosures | |
| Roughly 25.0% of Revelation Biosciences outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026 |
- Analyzing Revelation Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Revelation Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Revelation Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Revelation Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Revelation Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Revelation Biosciences' stock. These opinions can provide insight into Revelation Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Revelation Stock analysis
When running Revelation Biosciences' price analysis, check to measure Revelation Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Revelation Biosciences is operating at the current time. Most of Revelation Biosciences' value examination focuses on studying past and present price action to predict the probability of Revelation Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Revelation Biosciences' price. Additionally, you may evaluate how the addition of Revelation Biosciences to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |